/PRNewswire/ Hagens Berman urges PureCycle Technologies, Inc. (NASDAQ: PCT) investors with significant losses to submit your losses now. A class action has.
SAN FRANCISCO, May 08, 2021 (GLOBE NEWSWIRE) Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Aterian (ATER) Investors with Losses to Contact Its Attorneys Now, Firm Investigating Possible Securities Law Violations
News provided by
Share this article
f/k/a Mohawk Group Holdings
(MWK) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.
Investigation:
The investigation focuses on Aterian s statements concerning the capabilities and marketability of its purported end-to-end cloud-based platform, Artificial Intelligence Marketplace Ecommerce Engine (AIMEE).
In past quarters, Aterian has touted AIMEE s functionality, claiming it allows users to leverage machine learning, natural language processing and data analytics. Aterian has stated that AIMEE in turn allows users to streamline the management of product
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed
News provided by
Share this article
Class Period: June 15, 2020 - Apr. 4, 2021
Lead Plaintiff Deadline: June 18, 2021
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:
The complaint alleges that Defendants misrepresented facts concerning Acadia s supplemental new drug application ( sNDA ) for NUPLAZID® (pimavanserin), which treats dementia-related psychosis ( DRP ).
Specifically, on July 20, 2020, Acadia announced the FDA accepted for filing the sNDA and stated that its pivotal study for the drug showed a meaningful reduction of psychosis symptoms and a nearly 3X reduction in the risk of relapse for patients continuing on pimavanserin vs. placebo. Thereafter, the company repeatedly stated the FDA h
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Canaan (CAN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Case Filed
News provided by
Share this article
SAN FRANSISCO, April 19, 2021 /PRNewswire/ Hagens Berman urges Canaan Inc.
(NASDAQ: CAN) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.
Class Period: Feb. 10, 2021 – Apr. 9, 2021
Lead Plaintiff Deadline: June 14, 2021
The complaint is focused on Canaan s statements about its bitcoin mining machine business.
According to the complaint, in past months, Canaan has falsely touted substantial improvement in its revenue visibility, its ability to more precisely forecast revenues, and its receipt of larger orders for its bitcoin mining machines. As recently as Apr. 9, 2021, Canaan s CEO reportedly assured